Online citations, reference lists, and bibliographies.
← Back to Search

Intranasal Delivery Of Therapeutic Proteins For Neurological Diseases

F. Malerba, Francesca Paoletti, S. Capsoni, Antonino Cattaneo
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: Among the range of therapeutic protein candidates for new generation treatments of neurological diseases, neurotrophic factors and recombinant antibodies hold the greatest potential. However, major difficulties in their safe and effective delivery to the brain severely limit these applications. The BBB restricts the exchange of proteins between the plasma and the CNS. Moreover, therapeutic proteins often need to be selectively targeted to the brain, while minimizing their biodistribution to systemic compartments, to avoid peripheral side effects. The intranasal delivery of proteins has recently emerged as a non-invasive, safe and effective method to target proteins to the CNS, bypassing the BBB and minimizing systemic exposure. Areas covered: We critically summarize the main experimental and mechanistic facts about the simple and non-invasive nasal delivery approach, which provides a promising strategy and a potential solution for the severe unmet medical need of safely and effectively delivering protein therapeutics to the brain. Expert opinion: The intranasal route for the effective delivery of recombinant therapeutic proteins represents an emerging and promising non-invasive strategy. Future studies will achieve a detailed understanding of pharmacokinetic and mechanisms of delivery to optimize formulations and fully exploit the nose-to-brain interface in order to deliver proteins for the treatment of neurological diseases. This expanding research area will most likely produce exciting results in the near future towards new therapeutical approaches for the CNS.
This paper references
10.1385/1-59259-419-0:385
Molecular biology of the blood-brain barrier.
W. Pardridge (2005)
10.1016/j.jstrokecerebrovasdis.2009.09.005
Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model.
M. Guerra-Crespo (2010)
10.1080/10611860701453653
Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery
A. Jain (2007)
10.1006/mcne.2002.1163
β-Amyloid Plaques in a Model for Sporadic Alzheimer's Disease Based on Transgenic Anti-Nerve Growth Factor Antibodies
S. Capsoni (2002)
10.1038/nbt1204-1513
Recombinant protein therapeutics—success rates, market trends and values to 2010
Alex K. Pavlou (2004)
Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte Malerba, Paoletti, Capsoni & Cattaneo Expert Opin. Drug Deliv
M Miyamoto (2001)
10.1002/jps.21939
Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations.
M. Migliore (2010)
10.1038/nn938
Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
H. Thoenen (2002)
10.1111/j.1460-9568.2007.05883.x
Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain
Veronica di Fausto (2007)
10.1016/j.brainres.2006.09.102
Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: Biochemical and structural evidence
A. Lambiase (2007)
10.1016/J.DRUDIS.2006.10.013
Blood-brain barrier delivery.
W. Pardridge (2007)
10.1007/BF00237470
Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat
H. Baker (2004)
10.1152/ajpregu.1999.276.3.R818
Contribution of extracranial lymphatics and arachnoid villi to the clearance of a CSF tracer in the rat.
M. Boulton (1999)
10.1523/JNEUROSCI.23-24-08532.2003
Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice
P. Das (2003)
10.1016/J.YMTHE.2006.02.018
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain.
P. Hadaczek (2006)
10.1371/journal.pone.0017321
Taking Pain Out of NGF: A “Painless” NGF Mutant, Linked to Hereditary Sensory Autonomic Neuropathy Type V, with Full Neurotrophic Activity
S. Capsoni (2011)
10.1002/(SICI)1097-4695(199608)30:4<521::AID-NEU7>3.0.CO;2-5
Adenovirus-mediated gene transfer in olfactory neurons in vivo.
H. Zhao (1996)
CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.
R. Mandel (2010)
10.1038/NBT0606-595
Monoclonals expand into neural disorders
B. Vastag (2006)
10.1371/journal.pone.0011085
Liposome-siRNA-Peptide Complexes Cross the Blood-Brain Barrier and Significantly Decrease PrPC on Neuronal Cells and PrPRES in Infected Cell Cultures
B. Pulford (2010)
10.1016/j.peptides.2008.09.026
Identification of nose-to-brain homing peptide through phage display
Xiao-mei Wan (2009)
10.1016/j.neuron.2008.01.003
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
B. Zlokovic (2008)
10.3390/molecules14093754
Nasal Delivery of High Molecular Weight Drugs
Y. Ozsoy (2009)
10.1007/s002219900229
Transfer of tritiated water, tyrosine, and propanol from the nasal cavity to cranial arterial blood in rats
N. Einer-Jensen (1999)
10.1177/0333102409359314
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
P. Djupesland (2010)
A new generation of noninvasive NGF-based therapies for Alzheimer's Disease
A Cattaneo (2010)
10.1002/jps.21924
Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
S. Dhuria (2010)
Gene Knockdown in the Olfactory Bulb, Amygdala, and Hypothalamus
I Kim (2009)
10.3233/JAD-2008-13309
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
M. Reger (2008)
10.1016/j.neuroscience.2008.01.013
Delivery of interferon-β to the monkey nervous system following intranasal administration
R. Thorne (2008)
10.1038/nbt1142
Engineered antibody fragments and the rise of single domains
P. Holliger (2005)
10.1523/JNEUROSCI.5538-09.2010
Oxytocin Enhances Amygdala-Dependent, Socially Reinforced Learning and Emotional Empathy in Humans
R. Hurlemann (2010)
10.1016/S0014-2999(00)00540-9
Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology?
H. Fehm (2000)
10.1023/A:1016254514167
Cerebrovascular Permeability to Peptides: Manipulations of Transport Systems at the Blood-Brain Barrier
B. Zlokovic (2004)
Clearance of amyloid beta-peptide from brain: transport or metabolism?
Zlokovic (2000)
10.1007/BF00296784
Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain
E. T. Zhang (2004)
10.1021/bm800975j
New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules.
D. Teijeiro-Osorio (2009)
Gene Knockdown in the Olfactory Bulb, Amygdala, and Hypothalamus by Intranasal siRNA Administration
I Kim
10.3109/00016488909125526
The olfactory and respiratory epithelium in rhesus and squirrel monkeys studied with freeze-fracture technique.
B. Engström (1989)
10.1016/j.psyneuen.2004.04.003
Intranasal insulin improves memory in humans
Christian Benedict (2004)
10.1073/PNAS.0500195102
Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice.
Roberta De Rosa (2005)
10.1111/j.1460-9568.2006.04642.x
Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin‐4/5 in pyramidal cell neuroprotection
N. Royo (2006)
10.18433/J3NC79
Intranasal drug delivery: how, why and what for?
A. Pires (2009)
10.1016/J.JCONREL.2006.03.011
Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats.
J. Wang (2006)
10.3233/JAD-2008-15205
Filamentous bacteriophage as a novel therapeutic tool for Alzheimer's disease treatment.
B. Solomon (2008)
10.1016/S0378-5173(03)00039-5
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.
C. Dufès (2003)
10.1016/0006-8993(85)91383-6
Evidence for a ‘Paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space
M. Rennels (1985)
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.
P. Das (2003)
10.3233/JAD-2008-15210
Towards non invasive nerve growth factor therapies for Alzheimer's disease.
Antonino Cattaneo (2008)
10.1016/j.neuroscience.2004.05.029
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
R. Thorne (2004)
10.1016/S0079-6123(08)00428-7
Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans.
M. Heinrichs (2008)
10.1016/j.peptides.2010.04.011
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse—A microtubule-deficient model of schizophrenia
A. Merenlender-Wagner (2010)
10.1007/BF00453492
Fenestrated endothelia in vessels of the nasal mucosa
G. Grevers (2004)
10.1016/J.JCONREL.2007.05.026
Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
X. Gao (2007)
10.3109/10717549709051878
Delivery of 125I-NGF to the Brain via the Olfactory Route
W. Frey (1997)
10.1111/j.1743-6109.2007.00691.x
Male anorgasmia treated with oxytocin.
W. Ishak (2008)
10.1201/9780203911457.CH1
Anatomy of the Human Nasal Passages
D. M. Clerico (2003)
10.1016/j.neuroscience.2008.05.040
Nasal administration of cholera toxin B subunit–nerve growth factor improves the space learning and memory abilities in β-amyloid protein25-35-induced amnesic mice
Q. Zhang (2008)
10.1016/j.ijpharm.2009.06.019
Nanoparticles for direct nose-to-brain delivery of drugs.
Alpesh Mistry (2009)
10.1016/J.GDE.2003.08.001
Mesoangioblasts--vascular progenitors for extravascular mesodermal tissues.
G. Cossu (2003)
10.1038/nm1239
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
M. Tuszynski (2005)
Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barriers.
B. Zlokovic (1990)
10.1038/nbt0905-1073
Monoclonal antibody successes in the clinic
J. Reichert (2005)
10.1211/0022357022539
Is nose‐to‐brain transport of drugs in man a reality?
L. Illum (2004)
10.1073/pnas.072027199
Filamentous phage as vector-mediated antibody delivery to the brain
D. Frenkel (2002)
10.1038/nature05901
Transvascular delivery of small interfering RNA to the central nervous system
P. Kumar (2007)
10.1007/s11095-008-9550-2
Evaluation of Direct Transport Pathways of Glycine Receptor Antagonists and an Angiotensin Antagonist from the Nasal Cavity to the Central Nervous System in the Rat Model
S. Charlton (2008)
10.3109/10673220903523615
The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.
K. Macdonald (2010)
10.3109/10717544.2011.557785
Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia
W. Zhu (2011)
Target site of intranasally sprayed substances and their transport across the nasal mucosa : a new insight into the intranasal route of drug delivery
P Gopinath (1978)
10.1001/ARCHNEUR.1990.00530110068019
IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis.
J. Engelhardt (1990)
10.1016/J.BIOMATERIALS.2006.01.038
Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.
X. Gao (2006)
10.1016/j.neurobiolaging.2005.03.016
Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype
M. Reger (2006)
10.1001/ARCHNEUR.58.9.1395
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.
J. Price (2001)
Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: A new strategy for the treatment of narcolepsy
LR Hanson (2004)
10.1523/JNEUROSCI.22-18-07873.2002
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
B. Bacskai (2002)
10.1016/j.jmb.2009.01.061
Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
G. Meli (2009)
10.1002/cne.10143
Trigeminal collaterals in the nasal epithelium and olfactory bulb: A potential route for direct modulation of olfactory information by trigeminal stimuli
Michele L. Schaefer (2002)
Local vascular pathway for progesterone transfer to the brain after nasal administration in gilts.
J. Skipor (2003)
Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
I. Gozes (2000)
Intranasal insulin improves cognition and modulates beta-amyloid in early AD.
M. Reger (2008)
10.2174/138920108786786358
Monoclonal antibodies as innovative therapeutics.
J. Reichert (2008)
10.1002/JPS.20318
Nasal drug administration: potential for targeted central nervous system delivery.
Candace L. Graff (2005)
10.1016/j.biopsych.2010.04.039
Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients
D. Feifel (2010)
10.1016/J.IJPHARM.2007.03.025
Intranasal delivery: physicochemical and therapeutic aspects.
H. Costantino (2007)
10.1152/AJPRENAL.1981.240.4.F329
Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit.
M. Bradbury (1981)
10.2165/00003088-200746070-00002
Strategies to Improve Drug Delivery Across the Blood-Brain Barrier
A. Boer (2007)
Neurogenesis in the adult olfactory neuroepithelium
A. Mackay-Sim (2003)
10.1016/j.biopsych.2009.09.020
Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders
A. Guastella (2010)
10.1177/000348940511400808
Adenovirus-Mediated Gene Transfer in Olfactory Epithelium and Olfactory Bulb: A Long-Term Study
K. Doi (2005)
10.1016/S0002-9343(99)00011-X
Neurotrophic factors in the therapy of diabetic neuropathy.
S. Apfel (1999)
10.1016/j.jneuroim.2009.08.005
Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain
Esther Furrer (2009)
10.1111/j.1460-9568.2003.03075.x
Herpes simplex virus type 1 inoculation enhances hippocampal excitability and seizure susceptibility in mice
H. Wu (2003)
10.3233/JAD-2009-0953
Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice.
S. Capsoni (2009)
10.1016/j.brainresrev.2008.07.007
New insights into brain BDNF function in normal aging and Alzheimer disease
L. Tapia-Arancibia (2008)
10.1007/s00109-006-0114-9
Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy
I. Han (2006)
10.1016/S0278-6915(02)00215-6
Purification and acute toxicity of a lectin extracted from tepary bean (Phaseolus acutifolius).
R. Reynoso-Camacho (2003)
10.1124/JPET.103.063222
Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
W. Banks (2004)
10.1016/j.ejcb.2009.02.001
Intranasal delivery of cells to the brain.
L. Danielyan (2009)
10.1016/0006-8993(95)00637-6
Quantitative analysis of the olfactory pathway for drug delivery to the brain
R. Thorne (1995)
10.1126/SCIENCE.3306916
The nerve growth factor 35 years later.
R. Levi-Montalcini (1987)
Original ArticleIntranasal Administration of PEGylated Transforming Growth Factor-α Improves Behavioral Deficits in a Chronic Stroke Model
Magda Guerra-Crespo (2010)
10.3233/JAD-1998-1102
Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway.
X. Chen (1998)
10.1016/j.bbrc.2009.11.146
In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V.
S. Covaceuszach (2010)
10.1016/j.neuron.2010.08.007
Neuronal Activity Drives Localized Blood-Brain-Barrier Transport of Serum Insulin-like Growth Factor-I into the CNS
T. Nishijima (2010)
a new insight into the intranasal route of drug delivery
P Gopinath (2011)
10.1002/1096-9071(200008)61:4<468::AID-JMV9>3.0.CO;2-9
Diagnosis and surveillance of herpes simplex virus infection of the central nervous system
F. Najioullah (2000)
10.1046/j.1469-7580.1997.19130337.x
Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes
H. Pollock (1997)
10.1073/PNAS.93.9.4229
Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.
B. Zlokovic (1996)
10.1002/JEMT.1070230105
Morphology of olfactory epithelium in humans and other vertebrates
E. Morrison (1992)
10.1212/01.WNL.0000265401.62434.36
Intranasal insulin improves cognition and modulates β-amyloid in early AD
M. Reger (2008)
10.1016/S0378-5173(01)00797-9
Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats.
M. Miyamoto (2001)
10.1039/9781849731072-00043
Chapter 17:A New Generation of Noninvasive NGF-Based Therapies for Alzheimer's Disease
Antonino Cattaneo (2010)
10.1212/01.wnl.0000203120.85850.54
Axonal damage markers in cerebrospinal fluid are increased in ALS
J. Brettschneider (2006)
10.1023/A:1018901302450
Chitosan as a Novel Nasal Delivery System for Peptide Drugs
L. Illum (2004)
10.1038/nn0602-849
Sniffing neuropeptides: a transnasal approach to the human brain
J. Born (2002)
10.2174/156720509787602870
Development of a non invasive NGF-based therapy for Alzheimer's disease.
S. Covaceuszach (2009)
Controlled particle dispersion: applying vortical flow to optimize nasal drug delivery
M. Giroux (2007)
10.1038/nm.1912
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
A. Nagahara (2009)
10.1002/CNE.902510209
Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey
B. Balin (1986)
10.1167/IOVS.05-0301
Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats.
A. Lambiase (2005)
10.1016/J.YMTHE.2005.12.013
Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice.
J. M. Laing (2006)
10.1159/000106378
Intranasal Insulin to Improve Memory Function in Humans
Christian Benedict (2007)
10.1016/j.psyneuen.2010.12.005
Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities
M. Quirin (2011)
10.3109/10611860903318134
Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS
S. R. Alcala-Barraza (2010)
10.1016/j.pneurobio.2009.04.001
Oxytocin: The great facilitator of life
H. Lee (2009)
10.1038/nrd2399
Protein therapeutics: a summary and pharmacological classification
B. Leader (2008)
10.1523/JNEUROSCI.4182-09.2010
Ciliary Neurotrophic Factor Cell-Based Delivery Prevents Synaptic Impairment and Improves Memory in Mouse Models of Alzheimer's Disease
P. Garcia (2010)
10.1016/S0140-6736(87)92288-4
UPTAKE OF ALUMINIUM INTO CENTRAL NERVOUS SYSTEM ALONG NASAL-OLFACTORY PATHWAYS
D. Perl (1987)
Controlled Particle Dispersion™: Applying Vortical Flow to Optimize Nasal Drug Deposition
M. Giroux (2005)
10.1097/WAD.0b013e318068d6d2
Nerve Growth Factor Gene Therapy in Alzheimer Disease
M. Tuszynski (2007)
10.1081/LPR-100108460
ENHANCEMENT OF NASAL ABSORPTION OF CALCITONIN LOADED IN LIPOSOMES
S. Law (2001)
10.1517/17425247.3.6.707
The CNS as a target for peptides and peptide-based drugs
W. Banks (2006)
10.1007/978-1-59745-191-8_6
Nasal delivery of siRNA.
V. Bitko (2008)
10.1016/j.neulet.2008.04.097
Intranasal administration delivers peptoids to the rat central nervous system
T. M. Ross (2008)
10.1016/J.IJPHARM.2007.03.039
UEA I-bearing nanoparticles for brain delivery following intranasal administration.
X. Gao (2007)
BDNF intranasal administration rescues visual memory deficits in a mouse model of Alzheimer disease (AD), the AD11 mouse
N Berardi (2008)
Gene delivery into the central nervous system by nasal instillation in rats.
R. Drăghia (1995)
10.1038/sj.npp.1300021
Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
E. Hollander (2003)
10.1002/ANA.410360221
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects
B. Petty (1994)
10.1523/JNEUROSCI.3984-05.2005
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
P. Kirsch (2005)
Mesoangioblast-based supplementation of neurotrophic factors for the treatment of neuronal damage
A. Binaschi (2010)
10.1111/J.1527-3458.2005.TB00053.X
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
I. Gozes (2005)
10.1016/J.PNEUROBIO.2007.01.003
Role of brain-derived neurotrophic factor in Huntington's disease
C. Zuccato (2007)
10.1016/J.TIPS.2006.10.002
Angels and demons: neurotrophic factors and epilepsy.
M. Simonato (2006)
10.1016/0361-9230(85)90129-7
Transport of molecules from nose to brain: Transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium
M. Shipley (1985)
10.1016/S0168-3659(02)00363-2
Nasal drug delivery--possibilities, problems and solutions.
L. Illum (2003)
10.2165/00003088-200140120-00003
Delivery of Neurotrophic Factors to the Central Nervous System
R. Thorne (2001)
10.1016/0169-328X(96)00085-X
Efficient adenoviral vector-directed expression of a foreign gene to neurons and sustentacular cells in the mouse olfactory neuroepithelium.
A. Holtmaat (1996)
10.1073/pnas.192442999
Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice
S. Capsoni (2002)
10.1038/nrneurol.2010.68
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
C. Lemere (2010)
10.1002/jps.21674
Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake.
S. R. K. Vaka (2009)



This paper is referenced by
10.1007/s12035-018-1109-6
Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease
A. E. Aly (2018)
IGF-I in animal models of muscle wasting , neuromuscular disorders and injury Sarcopenia
Yao-Hua Song (2013)
10.3233/JAD-140498
A therapeutic approach for senile dementias: neuroangiogenesis.
C. Ambrose (2015)
10.1016/j.neuroscience.2015.07.016
Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats
T. Bender (2015)
10.1016/j.bmc.2017.11.001
Nose-to-brain peptide delivery - The potential of nanotechnology.
Eleni Samaridou (2018)
10.1039/c6nr07581a
Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles.
E. Ahmad (2017)
10.1371/journal.pone.0037555
Intranasal “painless” Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice
S. Capsoni (2012)
10.1016/j.biotechadv.2015.01.010
Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers.
M. Witting (2015)
10.1016/j.apmt.2020.100556
TAT modification facilitates nose-to-brain transport of intact mPEG-PDLLA micelles: Evidence from aggregation-caused quenching probes
E. Ahmad (2020)
RECENT DEVELOPMENTS IN TARGETED DRUG DELIVERY SYSTEM FOR CROSSING BLOOD- BRAIN BARRIER: A REVIEW
S. Kumar (2012)
10.3109/21691401.2016.1160405
Preliminary studies for the development of intranasal nanoemulsion containing CNS agent: emphasizing the utilization of cut and weigh method
A. Kumar (2017)
10.1111/bph.12312
Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives
G. Herradón (2014)
10.1016/j.biomaterials.2012.08.070
Airway delivery of peptides and proteins using nanoparticles.
C. Dombu (2013)
10.3233/JAD-122419
Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.
Chun Xiao (2013)
10.1016/j.imbio.2016.09.017
The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease.
Keith Rubin (2017)
10.1517/17425247.2015.1069815
Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier
A. E. Aly (2015)
10.1021/cn300191b
Noninvasive and targeted drug delivery to the brain using focused ultrasound.
A. Burgess (2013)
10.1016/j.ijbiomac.2014.08.052
Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery.
J. Sarvaiya (2015)
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.
Mihir B. Chauhan (2015)
10.1016/j.drudis.2013.07.010
Neurotrophin delivery using nanotechnology.
A. Angelova (2013)
10.2147/IJN.S69845
Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood–brain barrier
X. Wang (2014)
10.1016/j.phrs.2018.10.028
Painless Nerve Growth Factor: A TrkA biased agonist mediating a broad neuroprotection via its actions on microglia cells
Antonino Cattaneo (2019)
A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment.
C. Srisawat (2016)
10.1016/j.neuropharm.2018.02.006
Intranasal BDNF administration promotes visual function recovery in adult amblyopic rats
Gabriele Sansevero (2019)
10.1016/j.tem.2013.03.004
The therapeutic potential of IGF-I in skeletal muscle repair
Yao-hua Song (2013)
10.1016/j.lfs.2020.117540
Insulin mediated novel therapies for the treatment of Alzheimer's disease.
S. K. Dubey (2020)
10.1007/978-1-4614-9105-7_13
Pharmacoeconomic Considerations in CNS Drug Development
D. L. Gray (2014)
10.1007/978-1-4939-3634-2_9
Delivery of Peptides and Proteins to the Brain Using Nano-Drug Delivery Systems and Other Formulations
D. Stepensky (2016)
10.1016/B978-0-12-803581-8.09288-2
4.30 Nanomaterials for Drug Delivery to the Brain
A. Gaudin (2017)
10.1007/s12247-018-9343-z
Lamotrigine Lipid Nanoparticles for Effective Treatment of Epilepsy: a Focus on Brain Targeting via Nasal Route
Puja K. Gangurde (2018)
10.1177/1759091420930865
Proneurotrophins Induce Apoptotic Neuronal Death After Controlled Cortical Impact Injury in Adult Mice
Laura Montroull (2020)
10.1016/j.phrs.2017.03.020
Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease
Célia M. C. Faustino (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar